Chemotherapy-induced Symptoms in Sarcoma Patients and the Impact of Tumor Burden

Completed

• Conditions: Soft Tissue Sarcoma
• Interventions: Other: Questionnaires

• Registration Number: NCT01136824
• Lead Sponsor: University of Pittsburgh

Brief Summary

Assessments (survey data) in this study are designed to sample the symptom burden of patients undergoing adjuvant and neoadjuvant chemotherapy in the hospital. There will be no change in the treatment plan for these patients.

Detailed Description

Not available

Study Timeline

• Study Start: 2010-06
• Study First Submitted: 2010-06-02
• Study First Submitted QC: 2010-06-02
• Study First Posted: 2010-06-03
• Primary Completion: 2014-05
• Study Completion: 2014-05
• Status Verified: 2016-07
• Last Update Submitted: 2016-07-26
• Last Update Posted: 2016-07-27

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 11

Inclusion Criteria

• Patients who are receiving doxorubicin plus ifosfamide (AI)

Read More

Exclusion Criteria

• There is no exclusion criteria

Read More

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Sarcoma Subjects	Questionnaires	Soft tissue sarcoma patients treated with the adjuvant and neoadjuvant chemotherapy protocol of doxorubicin plus ifosfamide (AI)

Primary Outcome Measures

Name	Time	Method
To determine the extent of symptom burden and quality of life in sarcoma patients receiving AI chemotherapy.	2 years

Trial Locations

Locations (1)

University of Pittsburgh, Hillman Cancer Center; 🇺🇸 Pittsburgh, Pennsylvania, United States